Screening for prostate cancer.
2/5 보강
OpenAlex 토픽 ·
Prostate Cancer Diagnosis and Treatment
Global Cancer Incidence and Screening
Urologic and reproductive health conditions
Prostate cancer is the most commonly diagnosed cancer in UK men excluding non-melanoma skin cancer, with over 64,000 new cases and 12,000 deaths annually.
APA
Jonathan P. Bestwick, Nicholas Wald (2026). Screening for prostate cancer.. Journal of medical screening, 9691413261440207. https://doi.org/10.1177/09691413261440207
MLA
Jonathan P. Bestwick, et al.. "Screening for prostate cancer.." Journal of medical screening, 2026, pp. 9691413261440207.
PMID
41972986 ↗
Abstract 한글 요약
Prostate cancer is the most commonly diagnosed cancer in UK men excluding non-melanoma skin cancer, with over 64,000 new cases and 12,000 deaths annually. This disparity between incidence and mortality has fuelled debate about over-diagnosis and the value of screening. The UK National Screening Committee has advised against population prostate-specific antigen (PSA) screening, citing uncertainty regarding benefit and harm. However, a risk-based PSA screening algorithm that adjusts PSA levels to multiples of the median for the same age and incorporates age-specific risk demonstrated good screening performance (detection rate of 90% for a false-positive rate of 2%). The European Randomized Study of Screening for Prostate Cancer shows a 16% reduction in prostate cancer mortality with PSA screening, comparable to reductions achieved in bowel cancer screening. The addition of pre-biopsy multi-parametric magnetic resonance imaging (MRI) screening reduces unnecessary biopsies and over-diagnosis while maintaining detection of clinically significant disease. Together, risk-based PSA testing combined with multi-parametric MRI would prevent an estimated 13 prostate cancer deaths per 1000 men screened every 5 years from age 55, with 9 deaths prevented for every man treated unnecessarily.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Diagnostic performance of apparent diffusion coefficients for prostate cancer in patients with PI-RADS 4-5 lesions: a retrospective analysis.
- Does protocol heterogeneity in active surveillance influence clinical outcomes? Insights from a multicenter prostate cancer cohort.
- PrP-Neutralizing Antibody Confers an Additive Benefit in Combination with 5-Fluorouracil in KRAS-Mutant Colorectal Cancer Models, Associated with Reduced RAS-GTP and AKT/ERK Phosphorylation.